How to treat hyperparathyroidism
Reading File
Finding Sources
Searching PubMed
"hyperparathyroidism"[MeSH Terms] AND "treatment"[MeSH Terms]
Finding Sources
Searching PubMed
"hyperparathyroidism" AND "management"
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Let me compile a thorough answer.
Treatment of Hyperparathyroidism
Hyperparathyroidism has three forms — primary, secondary, and tertiary — each with distinct treatment strategies.
Primary Hyperparathyroidism (PHPT)
The most common cause is a solitary parathyroid adenoma; less commonly, multiglandular hyperplasia. Most cases today present as asymptomatic hypercalcemia detected on routine blood work.
1. Surgery (Definitive Treatment)
Parathyroidectomy is the only curative intervention, achieving cure in up to 98% of patients. It is indicated in:
All symptomatic patients — symptoms typically improve post-operatively and include:
- Nephrolithiasis, nephrocalcinosis, renal dysfunction
- Osteoporosis, fragility or vertebral fractures
- Neurocognitive symptoms (memory deficits, depression, fatigue)
- Pancreatitis, GI symptoms
Asymptomatic patients if any of the following are present (4th International Workshop Guidelines):
| Criterion | Threshold |
|---|---|
| Serum calcium | >1 mg/dL above upper limit of normal |
| eGFR | <60 mL/min |
| 24-hour urine calcium | >400 mg |
| Nephrolithiasis | Present |
| Bone mineral density | T-score ≤ −2.5 (any site), or vertebral fracture |
| Age | <50 years |
| Inability to comply with serial follow-up | — |
| Patient preference | — |
Operative approaches:
- Minimally invasive parathyroidectomy (MIP) — focused exploration of a single gland guided by preoperative localization; standard approach when concordant imaging is available
- Bilateral cervical exploration — used for multigland disease, MEN syndromes, or failed localization
- Intraoperative PTH monitoring — confirms adequate resection; PTH should fall >50% within 10 minutes of gland removal
- Cryopreservation of resected tissue is recommended in complex cases
Preoperative localization (does not establish diagnosis, only guides surgery):
- Neck ultrasound
- Tc-99m sestamibi scintigraphy ± SPECT
- 4D-CT (most sensitive at ~90%, especially for ectopic glands)
Postoperative monitoring: PTH and calcium at 2–4 weeks, then 6 months to confirm cure. Annual calcium long-term (recurrence in ~2%).
2. Medical Management (Non-Operative Candidates)
Reserved for patients who cannot or will not undergo surgery. Current medical therapies do not match the efficacy of surgery.
A. Calcimimetics — Cinacalcet (Sensipar)
- Acts as an allosteric activator of the calcium-sensing receptor (CaSR), mimicking high calcium and suppressing PTH secretion
- Dose: 30–180 mg/day orally
- Reduces serum calcium effectively but does not improve bone density
- Indicated in: inoperable patients, failed surgery, or parathyroid carcinoma
B. Bisphosphonates (e.g., alendronate)
- Improve bone mineral density at the lumbar spine and hip
- Do not significantly lower serum calcium
- Used for bone protection in patients managed conservatively
C. Observation/Serial monitoring (if no surgical indications):
- Annual serum calcium and PTH
- Bone densitometry every 1–2 years
- Renal imaging and eGFR every 1–2 years
- Adequate hydration; avoid thiazide diuretics and lithium (raise calcium)
- Ensure vitamin D sufficiency (replete cautiously, targeting 25-OH-D >20 ng/mL)
Secondary Hyperparathyroidism
Caused by chronic hypocalcemia — most commonly from chronic kidney disease (CKD) — leading to parathyroid gland hyperplasia.
Medical Management (First Line)
- Phosphate restriction — dietary reduction of phosphate intake
- Phosphate binders — calcium carbonate/acetate or non-calcium binders (sevelamer, lanthanum carbonate) to reduce intestinal phosphate absorption
- Active vitamin D analogs — calcitriol or paricalcitol to suppress PTH secretion
- Cinacalcet — reduces PTH by nearly 70% in dialysis patients not adequately controlled by phosphate binders + vitamin D; does not provide a proven survival benefit over vitamin D therapy alone
- Etelcalcetide — IV calcimimetic, an alternative for hemodialysis patients
Surgical Management
Renal transplantation is the only definitive cure for secondary hyperparathyroidism due to CKD.
Parathyroidectomy is indicated when (Bailey & Love criteria):
- Intact PTH persistently >500 pg/mL
- Hyperphosphatemia (PO₄ >6 mg/dL) or hypercalcemia refractory to medical therapy
- Largest gland volume >300–500 mm³ or long axis >1 cm
- Plus clinical features: severe osteitis fibrosa, bone/joint pain, muscle weakness, pruritus, progressive ectopic calcification, calciphylaxis
Surgical options (none clearly superior):
- Subtotal parathyroidectomy (3.5 glands removed)
- Total parathyroidectomy with forearm autograft
- Total parathyroidectomy without autograft
Calciphylaxis (calcific uraemic arteriolopathy) — mortality up to 87%; urgent parathyroidectomy improves pain, wound healing, and median survival.
Tertiary Hyperparathyroidism
Occurs after renal transplantation when autonomous PTH secretion persists despite restored renal function.
- Cinacalcet is a first-line option
- Parathyroidectomy if refractory (same principles as primary HPT)
Special Situations
MEN1/MEN2A: Subtotal (3.5 glands) or total parathyroidectomy with autograft; requires pre-operative pheochromocytoma workup in MEN2A.
Parathyroid carcinoma: Wide local excision of the tumor with ipsilateral thyroid lobe; cinacalcet for unresectable disease.
Pregnancy: Parathyroidectomy in the second trimester is safe when indicated; surveillance alone is reasonable in mild cases.
Sources: Current Surgical Therapy 14e, p. 904–909; Bailey and Love's Short Practice of Surgery 28e, p. 907; Robbins & Kumar Basic Pathology, p. 764; National Kidney Foundation Primer on Kidney Diseases 8e; Goldman-Cecil Medicine; Braunwald's Heart Disease.
This is a shared conversation. Sign in to Orris to start your own chat.